慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)是一种成熟B淋巴细胞克隆增殖性肿瘤,以淋巴细胞在外周血、骨髓、脾脏和淋巴结聚集为特征。CLL是西方国家最常见的成人白血病,大约占所有白血病的30%〔1〕,氟达拉滨(Flu)的问世结束了CLL的治疗长期依赖于苯丁酸氮芥(clb)的局面,利妥昔单抗(RTX)的出现更是显著提高了患者的完全缓解率。目前临床上以Flu、环磷酰胺和RTX联合治疗(FCR)为标准一线治疗方 Chronic lymphocytic leukemia (CLL) is a mature B lymphocyte clone-proliferating tumor characterized by accumulation of lymphocytes in peripheral blood, bone marrow, spleen and lymph nodes. CLL is the most common adult leukemia in western countries, accounting for about 30% of all leukemias [1]. The advent of fludarabine The treatment of CLL has long been dependent on the situation of chlorambucil (clb) Rituximab (RTX) is the emergence of significantly improved the patient's complete remission rate. At present, Flu, cyclophosphamide and RTX combination therapy (FCR) as the standard first-line treatment